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IL-1, TNF-, TGF-, and bFGF expression in bone biopsies end-stage renal failure. The main abnormalities are closely
before and after parathyroidectomy. linked to alterations in bone turnover. Uremic patients
Background. There is growing evidence pointing to an may suffer from high turnover bone disease with variousinvolvement of cytokines and growth factors in renal osteodys-
degrees of mineralization defect or low turnover osteo-trophy. In this study, the expression of interleukin-l (IL-1),
dystrophy. The pathogenesis of renal bone disease reliestumor necrosis factor- (TNF-), transforming growth fac-
tor- (TGF-), and basic fibroblast growth factor (bFGF) in mainly on alterations of the parathyroid hormone (PTH)-
bone biopsies taken from uremic patients before and 1 year vitamin D axis. In fact, the excessive PTH production
after parathyroidectomy (PTX) was evaluated. Biochemical observed in uremic patients can lead to the well-known
features and histomorphometric outcome were also studied.
secondary hyperparathyroidism state (HPT). However,Methods. Iliac bone biopsies were taken before and 1 year
only excess production of PTH alone does not com-after PTX in nine uremic patients with severe hyperparathy-
roidism (HPT). Immunohistochemical techniques were used pletely explain the bone abnormalities found in second-
to identify the expression of IL-1, TNF-, TGF-, and bFGF ary HPT. Recent evidences have introduced new insights
in these bone samples. in the interplay between PTH and cytokines involved in
Results. At the time of the second bone biopsy, the mean
the regulation of bone cells [1, 2]. In fact, high circulatingserum total alkaline phosphatase activity was normal, whereas
levels of cytokines and growth factors have been exten-mean serum intact parathyroid hormone (iPTH) level was
slightly above the upper limit of normal values. Histomorpho- sively documented in uremic patients [3]. The overpro-
metric analysis showed a decrease in resorption parameters duction of these mediators may have an important im-
and static bone formation parameters after PTX. Dynamically, pact on bone metabolism, regulating different stages of
mineral apposition rate (MAR) and mineralization surface
the bone remodeling cycle in patients with renal osteo-(MS/BS) decreased significantly. There was a marked local
dystrophy [4, 5].expression of IL-1, TNF-, TGF-, and bFGF in bone biop-
sies before PTX, particularly in fibrous tissue and resorption Interleukin-1 (IL-1) and tumor necrosis factor-
areas. One year after PTX, IL-1 decreased from 23.6  7.5% (TNF-) are potent stimulators of bone resorption, both
to 9.9  3.1%, TNF- from 4.5  1.5% to 0.7  0.8%, TGF- in vitro and in vivo [6]. The increased IL-1 plasma levels
from 49.6  9.8% to 15.2  4.6%, and bFGF from 50.9 
found in dialysis patients [3] may influence bone resorp-12.7% to 12.9  7.9% (P  0.001). A significant correlation
tion by promoting the differentiation of osteoclasts ini-was documented between cytokines and growth factors expres-
sion in bone with iPTH levels before and after PTX (P 0.05). tiating sites of bone erosion [7]. IL-1 may also stimulate
Conclusions. Based on these results, we suggest that IL-1, prostaglandin synthesis, which independently contributes
TNF-, TGF-, and bFGF are involved in bone remodeling to bone resorption [8]. On the other hand, IL-1 can inhibit
regulation, acting as local effectors, possibly under the control
bone formation, as demonstrated by in vitro experimentsof PTH.
[9]. TNF-, which has also been found to circulate at
high levels in uremic patients [3], has effects on bone
resorption similar to those of IL-1, but with less potencyRenal osteodystrophy comprises a variety of abnormal
[10]. TNF- stimulates the differentiation of osteoclastbone remodeling processes that develops in patients with
precursors into mature cells, enhancing osteoclast activ-
ity [11], and can also inhibit bone formation [12].
Key words: cytokines, growth factors, renal osteodystrophy. High concentrations of transforming growth factor-
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actions, enhancing bone cell formation [15], decreasing ous osteoclasts and resorptive surfaces. Bone biopsies
obtained from healthy skeletal of patients submitted toresorptive activity, and also attracting osteoblasts to re-
sorption lacunae, initiating bone formation [16]. Another surgical orthopedic composed the control group. Control
bone biopsies were examined with immunohistochemis-strong anabolic mediator of bone cells is basic fibroblast
growth factor (bFGF). When activated during bone re- try techniques. In addition, calcium, phosphate, AP activ-
ity, and iPTH were determinate in the serum samplessorption, bFGF is able to stimulate bone cell replication
and collagenous matrix modulation [17] and also pro- of these patients.
The patients were unresponsive to clinical treatment,motes neovascularization [18]. Based on these observa-
tions, abnormalities in cytokines and growth factors that including vitamin D therapy, or had uncontrolled hyper-
phosphatemia despite the use of phosphate restrictionact on bone are likely to be critical in the pathogenesis
of renal bone disease in patients with end-stage renal and phosphate-binding antacids. Six patients received
aluminum-containing phosphate binders for uncontrolledfailure.
The prolonged survival of patients maintained on dial- hyperphosphatemia. The other three patients received
calcium-containing binders. Therefore, all patients wereysis treatment has resulted in a growing number of ure-
mic patients suffering from severe HPT, characterized submitted to a total PTX, followed by heterotopic auto-
transplantation in the forearm. Thallium-technetiumby a marked increase in bone turnover, increased bone
resorption and formation. When medical treatment fails, scans were performed before surgery for localization of
glands.surgical reduction of the parathyroid gland mass may
become necessary [19]. Immediately after parathyroidec- After PTX, patients required high doses of calcium
(0.27  0.07 mg/kg/day) and calcitriol (0.045  0.006 g/tomy (PTX), intact plasma PTH (iPTH) declines abruptly
and persists at low levels for 1 to 2 years after surgery kg/day). Then, calcium supplements were maintained in
87% of patients during the first 12 months of follow-up[20]. Several reviews reporting the effects of PTX on
plasma biochemistry and on bone structure have been at 1.5  0.23 g/day and calcitriol at 0.23  0.12 g/day
in 74% of patients. These patients were reevaluated 1published [21, 22]. However, the effects of decreased
PTH on bone pathophysiology, as well as the local ex- year after PTX, with analyses of plasma calcium, phos-
phorus, AP, and iPTH. A second bone biopsy was alsopression of cytokines and growth factors, on long-term
skeletal survey have not been investigated. taken in each patient. Histomorphometric outcomes and
immunohistochemical analysis, that is IL-1, TNF-,In this study, a group of uremic patients with severe
HPT submitted to PTX was evaluated. The expression TGF-, and bFGF expression, were analyzed in bone
biopsies, comparing the samples before and 1 year afterof IL-1, TNF-, TGF-, and bFGF in bone biopsies
taken from these patients before and 1 year after PTX PTX. The Ethical Committee of the Hospital das Clinicas
of University of Sa˜o Paulo approved this study.was analyzed. Biochemical features and histomorphome-
tric outcome were also studied.
Biochemistry
Total serum calcium levels were measured by atomic
METHODS
absorption spectrophotometry (normal values, 8.8 to
Group studied 10.5 mg/dL) and inorganic serum phosphate by the color-
imetric method of Fisk-Subarrow (normal values, 2.8 toNine chronically uremic patients maintained on long-
term hemodialysis (mean, 47.4  18.1 months) were in- 4.8 mg/dL). Serum total AP activity was measured using
panitro-p-phosphate as a substrate (normal values included in the study. Seven patientes were refereed from
various hospitals of Sa˜o Paulo to our institution. Another adults, 50 to 190 U/L), and serum iPTH levels were
determined by immunoradiometric assay of iPTH (Cistwo patients entered long-term dialysis at University of
Sa˜o Paulo. The patients included six females and three Bio-International, Gif-Sur-Yvette, France) with refer-
ences values of 10 to 62 pg/mL.males, ages 15 to 48 years (mean, 34.9  11.3 years).
The underlying renal disease was divided into glomerular
Bone histologydisease (N  6), nephrosclerosis (N  2), and unknown
(N  1). The patients had severe HPT with markedly Bone biopsies were obtained from a standard site near
the anterior iliac crest using a Bordier trephine. Boneelevated serum levels of iPTH, ranging from 341 to 2246
pg/mL (mean, 1394  556 pg/mL), and elevated alkaline samples were fixed in 70% ethanol and processed for
histomorphometry, as reported by Malluche and Fau-phosphatase activity (AP) (1803  898 U). After in-
formed consent was obtained, the patients were submit- gere [23]. Prior to biopsy, all patients were prelabeled
with oral tetracycline (20 mg/kg/day, during 3 days), ad-ted to an iliac crest bone biopsy that corroborated the
severe HPT, including marrow fibrosis, accumulation of ministrated in two time-spaced doses, separated by an
interval of 10 days.woven bone and osteoid, increased number and activity
of osteoblasts, expansion of osteoid surfaces, and numer- Morphometric data were obtained from 5 m thick
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Table 1. Serum biochemical parameters before and 1 year aftersections of undecalcified toluidine-blue-stained sections
parathyroidectomy (PTX)
with a semiautomatic image analyzer Osteomeasure (Os-
Before PTX After PTX Controlteometrics, Inc., Atlanta, GA, USA). At least two non-
Serum calcium mg% 8.52.9 9.40.8 9.31.1consecutive sections were examined for each sample. All
Serum phosphorus mg% 7.01.3a 5.71.2a,b 3.80.6histomorphometric indices were reported according to
Alkaline phosphatase U/L 1803898a 10543b 81.319.8
the nomenclature recommended by the American Soci- iPTH pg/mL 1394556a 7097a,b 19.58.5
ety of Bone and Mineral Research (ASBMR) [24]. aP  0.05 vs. control
bP  0.05 vs. before PTXStatic bone histology included bone volume and fibro-
sis as a percentage of tissue volume, osteoid volume as
a percentage of bone volume, and osteoid thickness in
micrometers. Osteoid surface, osteoblast surface, osteoclast horse antimouse (Vector, Burlingame, CA, USA) to iden-
surface, and aluminum surface were expressed as percent- tify IL-1, horse antigoat for TNF-, goat antirabbit (Vec-
ages of total trabecular surface. Trabecular number and tor) to identify TGF- and bFGF. After rinsing in PBS
trabecular separation were expressed in micrometers. buffer, the slides were incubated with avidin-biotin per-
Dynamic bone parameters were obtained on unstained oxidase complex (ABC-kit, Vector). The slides were then
sections examined by fluorescence microscopy. The min- developed using the diaminobenzidine (DAB) substrate
eral apposition rate (MAR) was determined from the (Vector). The sections were rinsed in distilled water and
distance between the two tetracycline labels, divided by counterstained with haemalaum (Merck, Darmstadt, Ger-
the time interval between the administrations of the two many).
labels and expressed in micrometers per day. The per- Negative controls were carried out simultaneously
centage of double tetracycline-labeled surface of total with all experiments by omitting incubation with primary
trabecular surface (MS/BS) and bone formation rate antibodies. For additional negative controls, sections
(BFR) completed the dynamic evaluation. As normal were incubated with an irrelevant human immunoglobu-
control for Brazilian subjects was not available, the re- lin (IgG) (Sigma Chemical Co., St. Louis, MO, USA).
sults were compared to normal values reported for Euro- In addition, sections were also incubated with mouse
pean subjects by Bordier, Zingraff, Gueris [25], Meunier monoclonal anti-CD68 (Dako, Co., Glostrup, Denmark)
et al [26], and Charhon et al [27]. for a positive control.
Immunohistochemical method Quantitative analysis of cytokines and growth
factors expressionImmunostaining for IL-1, TNF-, TGF- and bFGF
was done with the avidin-biotin peroxidase method [28, The degree of IL-1, TNF-, TGF-, and bFGF ex-
29] on plastic embedded bone marrow iliac crest biop- pression in bone biopsies was measured by the point-
sies [30]. counting technique [31] at a magnification of100, using
The plastic mounted on the slides of sections was re- a 176-point ocular grid. Counting was performed on 25
moved by immersing them in acetone (Merck, Darm- microscopic fields for each bone sample. Each point was
stadt, Germany) for 12 hours at room temperature. Bone counted as either “positive” or “negative.” The area of
sections were rehydrated in graded alcohol solutions. To immunopositivity in the tissue was determined by point
block endogenous peroxidase, the hydrated specimens counting, determined as the number of positive points
were transferred to 3% hydrogen peroxide in 70% meth- in the tissue compared to the total number of points.
anol for 90 minutes. Prior to the immunostaining proce- For this study, two physicians evaluated all slides in a
dure, the sections were incubated with 5% normal serum blinded fashion without knowledge of the cases. The
from the same species of the secondary antibody to avoid results were analyzed as a percentage of total tissue.
nonspecific staining. The samples were then incubated
Statistical analysiswith avidin-biotin solutions to block nonspecific binding
of these compounds. Sections were incubated overnight Results are presented as mean  SD. ANOVA one-
at 4C in a humidified chamber using the primary anti- way test and Tukey post-test were used to compare the
bodies: monoclonal mouse antihuman IL-1 (R&D Sys- groups (before PTX, after PTX, and control group).
tems, Minneapolis, MN, USA), polyclonal goat antihuman Spearman’s correlation coefficient r was used for differ-
TNF- (R&D Systems), polyclonal rabbit antihuman ent correlation analysis.
TGF- (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), and polyclonal rabbit antihuman bFGF (Santa
RESULTSCruz Biotechnology).
Biochemical findingsAfter incubation with the primary antibody, sections
were rinsed in phosphate-buffered saline (PBS) buffer The biochemical data are presented in Table 1. Prior
to PTX, serum calcium levels were 8.5 2.9 mg%. Phos-and then incubated with biotinylated secondary antibody:
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Table 2. Static histomorphometric parameters before and one year after parathyroidectomy (PTX)
BV/TV OV/BV O.Th OS/BS Ob.S/BS Oc.S/BS Tb.Sp Tb. N FB.V Al.S/BS
% % mm % % % mm mm % %
Before PTX 41.43.8 25.04.5 17.71.5 65.96.0 24.54.0 2.20.5 163.725.8 4.00.4 23.74.2 16.76.9
After PTX 27.03.3 9.84.3 12.01.9 33.310.2 2.71.0 0.10.0 382.588.0 2.40.3 0.50.2 47.813
P 0.001 P  0.05 NS P  0.05 P 0.001 P 0.001 P  0.05 P 0.001 P 0.001 P  0.05
Abbreviations are: BV/TV, bone volume; OV/BV, osteoid volume; O.Th, osteoid thickness; OS/BS, osteoid surface; Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast
surface; Tb.Sp, trabecular separation; Tb. N, trabecular number; FB.V, fibrosis; Al.S/BS, aluminum surface; NS, not significant.
Table 3. Dynamic histomorphometric parameters before and 1 year (P  0.05), and osteoblast surface, 2.7  1.0% (P 
after parathyroidectomy (PTX)
0.001). Therefore, the mean volume of empty space in-
MAR MS/BS BRF/BS MLT creased (trabecular separation  382.5  88.0 mm; P 
lm/day % lm3/lm2/day days 0.05), and the solid material significantly decreased (tra-
Before PTX 1.70.2 18.12.5 0.30.1 41.211.2 becular number  2.4  0.3 mm; P  0.001). Fibrosis
After PTX 0.90.1 9.24.2 0.10.0 31.523.7
regressed in all patients (0.5  0.2%; P  0.001), butP 0.05 P  0.05 P  0.05 NS
aluminum surface increased significantly to 47.8  13%Abbreviations are: MAR, mineral apposition rate; MS/BS, mineralization
surface; BRF/BS, bone rate formation; MLT, mineralization lag time; NS, not (P  0.05).
significant. Dynamically, MAR and MS/BS decreased significantly
(0.9  0.1 m/day, and 9.2  4.2 m/day; P  0.05,
respectively). BFR decreased to 0.1  0.0 m3/m2/day
(P  0.05), and MLT to 31.5  23.7 days. Consequently,phorus was elevated in all patients of this study. Total
four patients developed aplastic lesions and two patientsserum AP and iPTH levels were substantially elevated
osteomalacia. Another two patients showed normal his-in all patients.
tology and one presented a mild lesion.One year after PTX, serum calcium was not signifi-
cantly different, but serum phosphorus levels decreased
Immunohistochemistry on bone biopsiessignificantly (P  0.05). AP activity and iPTH dropped
Control bone biopsies from healthy skeletal showeddramatically (P  0.001).
almost no staining for the cytokines and growth factors
Bone histomorphometry studied. In contrast, bone biopsies obtained from pa-
tients with HPT before PTX presented intense positivityPrior to PTX, bone histologic features were catego-
for IL-1, particularly in resorption areas and in medul-rized into osteitis fibrosis (N 4), characterized by mark-
lary fibrosis (Fig. 1A). In bone biopsies taken 1 yearedly increased osteoclastic activity, eroded bone sur-
after PTX, only a discrete staining for IL-1 was de-faces, marrow fibrosis, and no mineralization defects,
tected, mainly in the remaining fibrous tissue (Fig. 1B).and mixed lesions (N  5), comprising elements of both
There was a significant reduction in IL-1 immunostain-HPT and osteomalacia [23].
ing in biopsies, from 23.6  7.5% to 9.9  3.1% afterHistomorphometric analysis of bone biopsies taken
PTX (P  0.001). Normal control biopsies showed weakbefore PTX confirmed previous diagnosis of HPT. Biop-
immunostaining for IL-1 (0.70  0.09%, P  0.001 vs.sies showed an increase in resorption (osteoclast surface,
before PTX; P  0.05 after PTX) (Fig. 2).2.2 0.5%) and static bone formation parameters (oste-
TNF- expression in biopsies taken from patients withoid surface, 65.9  6.0%, and osteoblast surface, 24.5 
secondary HPT was observed mainly in resorption lacu-4.0%) (Table 2). A high degree of fibrosis was identified
nae, occupying 4.5  1.5% of total bone tissue (Fig.in bone marrow (23.7  4.2%), and aluminum deposits
1C). Only weak stain for TNF- was observed in bonecovered a mean of 16.7  6.9% of trabecular surfaces.
biopsies 1 year after PTX (0.7  0.8%), and a significantDynamically, the extent of bone surface that exhibited
decrease in TNF- expression was documented (P tetracycline fluorescence was increased (MAR, 1.7 0.2
0.001) (Fig. 1D). In control biopsies, almost no immuno-m/day, and MS/BS, 18.1  2.5%). Bone rate formation
staining for TNF- was observed (0.04  0.03%; P and mineralization lag time (MLT) were elevated (0.3 
0.001 vs. before PTX).0.1 m3/m2/day, and 41.2  11.2 days, respectively),
Figure 1E illustrates immunostaining for TGF- in aindicating increased bone formation rate and an absence
bone biopsy performed before PTX in a patient withof a mineralization defect (Table 3).
severe HPT. TGF- expression was detected particularlyBiopsies performed 1 year after PTX disclosed a sig-
in resorption lacunae and in the fibrotic marrow. In addi-nificant reduction in resorption parameters (osteoclast
tion, some cells exhibited immunopositivity for TGF-surface, 0.1  0%; P 0.001), and static bone formation
parameters decreased to osteoid surface, 33.3  10.2% in the tissue adjacent to the fibrotic marrow. Total quanti-
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Fig. 1. Immunohistochemistry for cytokines and growth factors in bone biopsies. Positive staining appears as brown color (100). (A ) Inter-
leukin-1 (IL-1) expression in medullar fibrosis and resorption areas in a patient with severe hyperparathyroidism (HPT). (B ) After parathyroidec-
tomy (PTX), only a discrete positivity for IL-1 is observed. (C ) Tumor necrosis factor- (TNF-) expression in resorptive lacunae before PTX.
(D ) Almost no TNF- staining after PTX. (E ) Intense immunostaining for transforming growth factor- (TGF-) in the fibrous area adjacent to
the cellular tissue. (F ) After PTX, a very weak immunostaining for TGF- is observed. (G ) basic fibroblast growth factor (bFGF) in the fibrotic
marrow replacement of the normal bone marrow tissue before PTX. (H ) Weak staining for bFGF in osteoid surface after PTX.
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Fig. 2. Quantitative expression of interleu-
kin-1 (IL-1) (A ), tumor necrosis factor-
(TNF-) (B ), transforming growth factor-
(TGF-) (C ), and basic fibroblast growth fac-
tor (bFGF) (D ) (%) of cytokines and growth
factors in bone biopsies before and 1 year
after parathyroidectomy (PTX). *P  0.001
vs. before PTX; #P  0.05 vs. after PTX.
tative staining counts for TGF- before PTX was 49.6  bone biopsies also demonstrated a significant correlation
9.8% of the total area. After PTX, TGF- expression with PTH circulating (iPTH), before and after PTX (Fig.
was detected only in areas adjacent to the lining cells 3). There was a significant correlation of IL-1 expres-
(Fig. 1F), occupying 15.2  4.6% of the total area (P  sion with iPTH levels (r  0.51, P  0.0317). TNF-
0.001 vs. before PTX). Control group showed a weak expression and iPTH also were significantly correlated
staining for TGF-, 0.05  0.0% (P  0.001 vs. before (r  0.74, P  0.0004). The growth factors, TGF- and
PTX and P  0.05 vs. after PTX). bFGF, were significantly correlated with iPTH (r 0.56,
Bone biopsies of HPT performed before PTX showed P  0.0150; and r  0.68, P  0.0021, respectively).
a marked staining for bFGF (50.9 12.7%) in the fibrotic
marrow replacement of the normal bone marrow tissue
DISCUSSION(Fig. 1G). Only a faint staining for this growth factor
The present study analyzed, by means of immunohis-appeared after PTX (12.9  7.9%; P  0.001) (Fig. 1H).
tochemistry, the expression of IL-1, TNF-, TGF-,In the control group, very weak immunostaining was
and bFGF in bone biopsies of patients submitted to PTX,detected (0.48  0.09%; P  0.001 vs. before PTX)
comparing the findings before and 1 year after surgical(Fig. 2).
removal of parathyroid glands. Histomorphometric out-Due to the marked expression of these cytokines and
come and biochemical parameters were also evaluated.growth factors observed in areas of bone marrow fibrosis,
Excessive PTH production in uremic patients is associ-a correlation between pathologic fibrosis and expression
ated with an increased mass of parathyroid tissue [32].of cytokines and growth factors before versus after PTX
The surgical correction of secondary HPT results in awas evaluated. There was a significant positive correlation
dramatic reduction of PTH secretion, as observed in thisin the extent of fibrosis with IL-1 expression (r  0.82,
study. A severe drop in AP followed this reduction inP  0.0001). Significant correlations were also observed
parathyroid activity, indicating decreased activity of os-with TNF- expression (r  0.65, P  0.0038), TGF-
teoblasts, in face of reduced osteoclastic activity.expression (r  0.89, P  0.0001), and bFGF expression
Histomorphometric analysis of bone biopsies taken be-(r  0.83, P  0.0001).
fore PTX confirmed the severity of the secondary HPT.The expression of IL-1 and TNF-, cytokines with
One year after PTX, the regression of HPT bone lesionsknown effects on bone resorption, were correlated with
was complete in eight patients, only one bone sampleosteoclast surface. The IL-1 and TNF- expression
still had mild lesions. This improvement in the bone isshowed significant correlation with osteoclast surface
expected from the decrease of the well-known hyper-(r  0.67, P  0.002; and r  0.75, P  0.0003, respec-
resorptive effect of PTH and indicates that PTX clearlytively).
Cytokine and growth factor expression detected in benefited patients who had histologic evidence in bone
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Fig. 3. Correlation between interleukin-1
(IL-1) (A ), tumor necrosis factor- (TNF-)
(B ), transforming growth factor- (TGF-)
(C), and basic fibroblast growth factor (bFGF)
(D ) expression in bone biopsies with intact
parathyroid (iPTH) levels before () and one
year after () parathyroidectomy (PTX).
of HPT preoperatively. Bone marrow fibrosis regressed The analysis of TNF- expression in bone biopsies dis-
closed similar results. Our immunohistochemical studiesin all patients, corroborating the evidence for correction
of severe bone lesions. However, osteomalacia or ady- revealed marked expression of TNF- in resorption lacu-
nae in bone biopsies from patients with HPT. Similar tonamic bone disease was reported in six patients, probably
a result of an excessive reduction in PTH secretion, which IL-1, TNF- stimulates bone resorption and inhibits
bone formation [9], but with less potency than IL-1can lead to inactive bone, so called “aplastic bone” [33].
In addition, PTX increased bone aluminum deposits, via [37]. The similar expression of IL-1 and TNF- in bone
biopsies and their similar biologic effects suggest thatdialysis water, probably due to favorable conditions for
the development of low turnover osteomalacia. these cytokines act in synergism in the regulation of bone
mass [6, 37].Bone biopsies performed before PTX showed a marked
staining for IL-1, TNF-, TGF-, and bFGF. One year In secondary HPT, overexpression of IL-1 and TNF-
may be a consequence of the uremic state, since highafter PTX, less intense staining for these mediators was
detected. IL-1 expression was intense in bone samples levels of these cytokines have been extensively demon-
strated in plasma samples of dialysis patients [3, 38]. Thewith HPT. Possible sources of IL-1 in bone are bone
marrow cells, where, in fact, IL-1 was detected. Immu- marked down-regulation of IL-1 and TNF- expression
observed in bone biopsies performed 1 year after PTX,nostaining of IL-1was also observed in eroded surfaces
of bone biopsies from patients with HPT, suggesting when plasma PTH activity reached normal levels, points
to a role of PTH in regulating local cytokine productionthat bone cells are not only targets of IL-1, but can
additionally synthesize this cytokine. The local produc- in bone tissue. A possible mechanism for bone resorption
is via protein kinase C activation by PTH in osteoblasts.tion of IL-1 suggests a pathogenic role of this mediator
in the mechanism of bone remodeling in HPT. The actions of PTH on bone resorption seem to occur
through osteoblast stimulation, which, in turn, producesIL-1 has been recognized as a potent bone-resorbing
factor, biologic effects based mainly on its ability in stim- osteoclastogenic factors, including cytokines. In this con-
text, IL-1, TNF-, and IL-6 can be components of thisulating osteoclast activity. Sabatini et al [34] demon-
strated that infusion of IL-1 in normal mice increased signaling pathway, enhancing bone resorbing [39]. Thus,
the actions of PTH on bone cell may occur through localthe number of osteoclasts and increased bone resorption
surfaces, causing hypercalcemia in these animals. On the cytokine activity at different stages of bone remodeling.
The development of bone marrow fibrosis and theother hand, blocking of IL-1 using antiserum com-
pletely inhibits bone-resorbing activity in cell cultures growth regulation of bone cells may be mediated by local
growth factors production [40]. The pathophysiology of[35], and the use of soluble form of IL-1 receptor antago-
nists attenuates bone erosion in rats [36]. marrow fibrosis in renal osteodystrophy has not been
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completely elucidated. In secondary HPT, little is known addition to decreased production of PTH, a net sup-
pressive effect of these local substances is possible, con-about the factors that contribute to the development of
marrow fibrosis. The extent of TGF- deposition in bone tributing to the low turnover status observed in bone
biopsies in secondary HPT observed in the present study biopsies. The markedly increased bone marrow fibrosis
suggests an involvement of this growth factor in the fi- found in bone biopsies with severe HPT had a significant
brotic response. TGF- can induce collagen synthesis positive correlation with cytokine and growth factor ex-
and fibroblast proliferation, critical steps for the develop- pression. These observations suggest that the effects of
ment of fibrosis [41]. In addition to the role of TGF- increased PTH activity are mediated by local production
in fibrogenesis, there is growing evidence that TGF- of cytokines and growth factors. These local substances
has anabolic activity in bone metabolism. During the exert cell-to-cell communication, signalizing several func-
bone remodeling cycle, TGF- decreases resorptive ac- tions in bone. At present, there is little information con-
tivity and attracts osteoblasts to resorptive lacunae, ini- cerning the direct involvement of cytokines in the devel-
tiating bone formation [17]. Our results demonstrated a opment of each stage of renal osteodystrophy. Advances
pronounced expression of TGF- on osteoid surface, in the recognition of disorders may lead to improved
suggesting local production of this growth factor. In sec- approaches to the prevention and treatment of bone dis-
ondary HPT, these anabolic effects of TGF- may be a ease. The possibility to assess various cytokines in bone
compensatory response to accelerated bone resorption. cells and their bone microenvironment should allow us
A balance between resorption and bone formation is to understand the intricate mechanisms of renal osteo-
required in order to maintain mechanical integrity. dystrophy.
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